# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ENDRA Life Sciences shares are trading lower by some 65% during Tuesday's session. The company priced a public offering of ...
Management believes that the meeting was highly informative and views the FDA's feedback as very constructive. Based on the...
ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $...